Richard Ascroft

“Let me share performance highlights for our reported sales of $155 million U.S. dollars for the quarter, declining by 8.2%. This decline is largely due to linoleumine erosion, as the U.S. business has grown by 6.5%.”

“Let me share the performance highlights for our U.S. business. Overall, the U.S. business reported sales of $427 million U.S. dollars for the quarter, declining by 9.7%.”

“We continue to see growth based on the model that we've adopted, and we also continue to see good growth of CEQA, a product that you didn't mention, where we think that will continue for the next years as well.”

“Let me share the performance highlights of our U.S. business. Our overall U.S. business was marginally up by 0.6% to reach $477 million for the quarter. Growth in innovative medicines was offset by lower sales in the generic business due to additional competition in certain products.”